• Something wrong with this record ?

Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA)

C. Gunduz, OK. Basoglu, J. Hedner, MR. Bonsignore, H. Hein, R. Staats, I. Bouloukaki, G. Roisman, A. Pataka, P. Sliwinski, O. Ludka, JL. Pepin, L. Grote, European Sleep Apnoea Database collaborators,

. 2019 ; 286 (6) : 676-688. [pub] 20190725

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20023418

BACKGROUND AND OBJECTIVE: Obstructive sleep apnoea (OSA) and hyperlipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and prevalence of hyperlipidaemia in patients of the European Sleep Apnea Database (ESADA) cohort. METHODS: The cross-sectional analysis included 11 892 patients (age 51.9 ± 12.5 years, 70% male, body mass index (BMI) 31.3 ± 6.6 kg/m2 , mean oxygen desaturation index (ODI) 23.7 ± 25.5 events/h) investigated for OSA. The independent odds ratio (OR) for hyperlipidaemia in relation to measures of OSA (ODI, apnoea-hypopnoea index, mean and lowest oxygen saturation) was determined by means of general linear model analysis with adjustment for important confounders such as age, BMI, comorbidities and study site. RESULTS: Hyperlipidaemia prevalence increased from 15.1% in subjects without OSA to 26.1% in those with severe OSA, P < 0.001. Corresponding numbers in patients with diabetes were 8.5% and 41.5%, P < 0.001. Compared with ODI quartile I, patients in ODI quartiles II-IV had an adjusted OR (95% CI) of 1.33 (1.15-1.55), 1.37 (1.17-1.61) and 1.33 (1.12-1.58) (P < 0.001), respectively, for hyperlipidaemia. Obesity was defined as a significant risk factor for hyperlipidaemia. Subgroups of OSA patients with cardio-metabolic comorbidities demonstrated higher prevalence of HL. In addition, differences in hyperlipidaemia prevalence were reported in European geographical regions with the highest prevalence in Central Europe. CONCLUSION: Obstructive sleep apnoea, in particular intermittent hypoxia, was independently associated with the prevalence of hyperlipidaemia diagnosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023418
003      
CZ-PrNML
005      
20201214130004.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/joim.12952 $2 doi
035    __
$a (PubMed)31260567
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Gunduz, C $u From the, Department of Chest Diseases, Biruni University, Istanbul, Turkey. Department of Chest Diseases, Ege University, Izmir, Turkey.
245    10
$a Hyperlipidaemia prevalence and cholesterol control in obstructive sleep apnoea: Data from the European sleep apnea database (ESADA) / $c C. Gunduz, OK. Basoglu, J. Hedner, MR. Bonsignore, H. Hein, R. Staats, I. Bouloukaki, G. Roisman, A. Pataka, P. Sliwinski, O. Ludka, JL. Pepin, L. Grote, European Sleep Apnoea Database collaborators,
520    9_
$a BACKGROUND AND OBJECTIVE: Obstructive sleep apnoea (OSA) and hyperlipidaemia are independent risk factors for cardiovascular disease. This study investigates the association between OSA and prevalence of hyperlipidaemia in patients of the European Sleep Apnea Database (ESADA) cohort. METHODS: The cross-sectional analysis included 11 892 patients (age 51.9 ± 12.5 years, 70% male, body mass index (BMI) 31.3 ± 6.6 kg/m2 , mean oxygen desaturation index (ODI) 23.7 ± 25.5 events/h) investigated for OSA. The independent odds ratio (OR) for hyperlipidaemia in relation to measures of OSA (ODI, apnoea-hypopnoea index, mean and lowest oxygen saturation) was determined by means of general linear model analysis with adjustment for important confounders such as age, BMI, comorbidities and study site. RESULTS: Hyperlipidaemia prevalence increased from 15.1% in subjects without OSA to 26.1% in those with severe OSA, P < 0.001. Corresponding numbers in patients with diabetes were 8.5% and 41.5%, P < 0.001. Compared with ODI quartile I, patients in ODI quartiles II-IV had an adjusted OR (95% CI) of 1.33 (1.15-1.55), 1.37 (1.17-1.61) and 1.33 (1.12-1.58) (P < 0.001), respectively, for hyperlipidaemia. Obesity was defined as a significant risk factor for hyperlipidaemia. Subgroups of OSA patients with cardio-metabolic comorbidities demonstrated higher prevalence of HL. In addition, differences in hyperlipidaemia prevalence were reported in European geographical regions with the highest prevalence in Central Europe. CONCLUSION: Obstructive sleep apnoea, in particular intermittent hypoxia, was independently associated with the prevalence of hyperlipidaemia diagnosis.
650    _2
$a kardiovaskulární nemoci $x epidemiologie $7 D002318
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hyperlipidemie $x epidemiologie $7 D006949
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x epidemiologie $7 D009765
650    _2
$a polysomnografie $7 D017286
650    _2
$a prevalence $7 D015995
650    _2
$a rizikové faktory $7 D012307
650    _2
$a obstrukční spánková apnoe $x epidemiologie $7 D020181
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Basoglu, O K $u Department of Chest Diseases, Ege University, Izmir, Turkey.
700    1_
$a Hedner, J $u Center for Sleep and Vigilance Disorders, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. Sleep Disorders Center, Pulmonary Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
700    1_
$a Bonsignore, M R $u Biomedical Department of Internal and Specialist Medicine (DiBiMIS), Section of Pneumology, University of Palermo, Palermo, Italy. CNR Institute of Biomedicine and Molecular Immunology, Palermo, Italy.
700    1_
$a Hein, H $u Sleep Disorders Center, St. Adolf Stift, Reinbeck, Germany.
700    1_
$a Staats, R $u Department of Respiratory Medicine, Hospital de Santa Maria, Lisbon, Portugal.
700    1_
$a Bouloukaki, I $u Sleep Disorders Unit, Department of Respiratory Medicine, University of Crete, Heraklion, Greece.
700    1_
$a Roisman, G $u Sleep Disorders Center, Antoine-Beclere Hospital, Clamart, France.
700    1_
$a Pataka, A $u Respiratory Failure Unit, G. Papanikolaou Hospital, Thessaloniki, Greece.
700    1_
$a Sliwinski, P $u 2nd Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
700    1_
$a Ludka, O $u Department of Cardiology, University Hospital Brno, Brno, Czech Republic. International Clinical Research Center, St. Ann's University Hospital, Brno, Czech Republic.
700    1_
$a Pepin, J L $u INSERM U1042, CHU de Grenoble, Université Grenoble Alpes, Grenoble, France.
700    1_
$a Grote, L $u Center for Sleep and Vigilance Disorders, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. Sleep Disorders Center, Pulmonary Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
710    2_
$a European Sleep Apnoea Database collaborators
773    0_
$w MED00010035 $t Journal of internal medicine $x 1365-2796 $g Roč. 286, č. 6 (2019), s. 676-688
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31260567 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130002 $b ABA008
999    __
$a ok $b bmc $g 1595737 $s 1114094
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 286 $c 6 $d 676-688 $e 20190725 $i 1365-2796 $m Journal of internal medicine $n J Intern Med $x MED00010035
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options